Chiasma, Inc. (NASDAQ:CHMA) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition.

On January8, 2018, Chiasma, Inc. (the “Company”) issued a press release providing a year-end corporate update and preliminary 2018 outlook, which press release included the Company’s preliminary approximate cash, cash equivalents and marketable securities as of December31, 2017. A copy of the press release is being furnished as Exhibit 99.1 to this Report on Form 8-K.

Reference is made to, and there is hereby incorporated by reference into this Item 2.02, the information set forth above under “Item 2.02. Results of Operations and Financial Condition” relating to preliminary approximate cash, cash equivalents and marketable securities as of December31, 2017.

The information in this Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

CHIASMA, INC Exhibit
EX-99.1 2 d517874dex991.htm EX-99.1 EX-99.1 Exhibit 99.1   Chiasma Reports on Significant Progress Made During 2017     •   Initiated CHIASMA OPTIMAL Phase 3 Clinical Trial after SPA agreement with FDA     •   Announces expected year-end 2017 cash and investments balance of approximately $67 million     •   Continues to expect existing cash and investments to be sufficient to fund operations through anticipated release of top-line data from CHIASMA OPTIMAL Phase 3 Clinical Trial by the end of 2019 WALTHAM,…
To view the full exhibit click here

About Chiasma, Inc. (NASDAQ:CHMA)

Chiasma, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body’s production of excess growth hormone. Octreotide is an analog of somatostatin, a natural inhibitor of growth hormone secretion. The Company is developing octreotide capsules as a liquid-filled solid gelatin capsule formulation, which is intended to be taken over twice a day. The Company’s TPE technology enhances the absorption through the intestinal wall of drugs. The Company also focuses on developing CH2 for Orphan indication.